CIK 0001789972 · Non-accelerated filer<br>Smaller reporting company
Cullinan Therapeutics, Inc.
Sign in to watch- Ticker
- CGEM
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 813879991
- Phone
- 617-410-4650
- Business address
- ONE MAIN STREET, SUITE 1350, CAMBRIDGE, MA, 02142
- Former names
- Cullinan Oncology, Inc., Cullinan Management, Inc., Cullinan Oncology, LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $222,000
- in 2 filings, $222K under 10b5-1 plans
Net −$222,000. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-02-17 | Savill Corrine Chief Business Officer | Grant or award · Stock Option (Right to Buy) | +41,000 | 41,000 | ||
| 2023-02-17 | SUMER JACQUELYN L Chief Legal Officer | Grant or award | +47,000 | 47,000 | ||
| 2023-02-17 | SUMER JACQUELYN L Chief Legal Officer | Grant or award · Stock Option (Right to Buy) | +93,500 | 93,500 | ||
| 2023-02-17 | Baeuerle Patrick Chief Scientific Officer | Grant or award | +38,500 | 76,000 | ||
| 2023-02-17 | Baeuerle Patrick Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +77,000 | 77,000 | ||
| 2023-02-17 | Michaelson Jennifer Chief Development Officer | Grant or award | +38,500 | 91,531 | ||
| 2023-02-17 | Michaelson Jennifer Chief Development Officer | Grant or award · Stock Option (Right to Buy) | +77,000 | 77,000 | ||
| 2023-02-17 | Jones Jeffrey Alan Chief Medical Officer | Grant or award | +60,000 | 60,000 | ||
| 2023-02-17 | Jones Jeffrey Alan Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +120,000 | 120,000 | ||
| 2023-01-19 | BVF PARTNERS L P/IL 10% owner | Other disposition | −3,500,000 | 558,854 | ||
| 2023-01-19 | BVF PARTNERS L P/IL 10% owner | Other disposition | −2,600,000 | 392,808 | ||
| 2023-01-19 | BVF PARTNERS L P/IL 10% owner | Other disposition | −300,000 | 64,161 | ||
| 2023-01-19 | BVF PARTNERS L P/IL 10% owner | Other acquisition · Series A Convertible Preferred Stock | +350,000 | 350,000 | ||
| 2023-01-19 | BVF PARTNERS L P/IL 10% owner | Other acquisition · Series A Convertible Preferred Stock | +260,000 | 260,000 | ||
| 2023-01-19 | BVF PARTNERS L P/IL 10% owner | Other acquisition · Series A Convertible Preferred Stock | +30,000 | 30,000 | ||
| 2022-12-30 | Trigilio Jeffrey Chief Financial Officer | Grant or award | +201 | $8.97 | $2K | 41,402 |
| 2022-11-25 | Michaelson Jennifer See Remarks | Option exercise | +4,000 | $4.30 | $17K | 57,031 |
| 2022-11-25 | Michaelson Jennifer See Remarks | Sale | −4,000 | $13.30 | $53K | 53,031 |
| 2022-11-25 | Michaelson Jennifer See Remarks | Option exercise · Stock Option (Right to Buy) | −4,000 | 200,593 | ||
| 2022-11-01 | Ryan David P. Director | Grant or award · Stock Option (Right to Buy) | +26,150 | 26,150 |
Page 11 of 23 · 446 trades